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Abstract
Background: Hepcidin, a key regulator of iron metabolism, is produced mainly by interleukin-6 (IL-6) during
inflammation. A mechanism linking cancer-related anemia and IL-6 through hepcidin production is suggested.
To clarify the hypothesis that overproduction of IL-6 elevates hepcidin levels and contributes to the development of
cancer-related anemia, we evaluated anti-IL-6 receptor antibody treatment of cancer-related anemia in an IL-6–producing
human lung cancer xenograft model.
Methods: Nude mice were subcutaneously inoculated with cells of the IL-6–producing human lung cancer cell
line LC-06-JCK and assessed as a model of cancer-related anemia. Mice bearing LC-06-JCK were administered
rat anti-mouse IL-6 receptor antibody MR16-1 and their serum hepcidin levels and hematological parameters
were determined.
Results: LC-06-JCK–bearing mice developed anemia according to the production of human IL-6 from xenografts, with
decreased values of hemoglobin, hematocrit, and mean corpuscular volume (MCV) compared to non–tumor-bearing
(NTB) mice. LC-06-JCK–bearing mice showed decreased body weight and serum albumin with increased serum
amyloid A. MR16-1 treatment showed significant inhibition of decreased body weight and serum albumin levels,
and suppressed serum amyloid A level. There was no difference in tumor volume between MR16-1-treated mice
and immunoglobulin G (IgG)-treated control mice. Decreased hemoglobin, hematocrit, and MCV in LC-06-JCK–bearing
mice was significantly relieved by MR16-1 treatment. LC-06-JCK–bearing mice showed high red blood cell counts and
erythropoietin levels as compared to NTB mice, whereas MR16-1 treatment did not affect their levels. Serum hepcidin
and ferritin levels were statistically elevated in mice bearing LC-06-JCK. LC-06-JCK–bearing mice showed lower values
of MCV, mean corpuscular hemoglobin (MCH), and serum iron as compared to NTB mice. Administration of MR16-1 to
mice bearing LC-06-JCK significantly suppressed levels of both serum hepcidin and ferritin, with increased values of
MCV and MCH.
Conclusions: Our results suggest that overproduction of hepcidin by IL-6 signaling might be a major factor that leads
to functionally iron-deficient cancer-related anemia in the LC-06-JCK model. We demonstrated that inhibition of
the IL-6 signaling pathway by MR16-1 treatment resulted in significant recovery of iron-deficiency anemia and
alleviation of cancer-related symptoms. These results indicate that IL-6 signaling might be one possible target
pathway to treat cancer-related anemia disorders.
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Background
Anemia is a major source of morbidity and mortality
worldwide [1]. Anemia is a common hematological ab-
normality in cancer patients; it impairs quality of life
and is associated with poorer response to the clinical
treatment and a worse prognosis. Therefore, a substan-
tial number of cancer patients require anemia treatment
[2, 3]. Low hemoglobin (Hb) levels correlate with poor
performance status in cancer patients [3].
Iron is an essential element for mammals as it is a
component of many key redox enzymes and oxygen
storage and transporting proteins such as Hb and myo-
globin [4]. Iron is strictly conserved, and iron from the
Hb of senescent red blood cells is recycled to provide
iron for new red blood cells. Dietary iron is absorbed
predominantly in the duodenum to replace the small
daily losses. Because mammals lack mechanisms to ex-
crete excess iron, intestinal iron absorption is regulated
by a feedback mechanism [5].
Hepcidin is a 25-amino acid peptide hormone pro-
duced mainly in the liver that regulates intestinal iron
absorption by causing degradation of the enterocyte iron
transporter ferroportin, iron recycling by macrophages,
and iron release from hepatic stores [4, 6]. Hepcidin se-
cretion is regulated by iron stores, oxygenation, and in-
flammatory signals.
Interleukin-6 (IL-6) plays a major role in the response
to injury and is involved in the immune response, in-
flammation, and hematopoiesis. IL-6 exerts various bio-
logical activities on responding cell populations through
its binding to transmembrane IL-6 receptor as well as to
soluble IL-6 receptor. Dysregulated continuous produc-
tion of IL-6 by a distinct cell population plays a patho-
logical role in various inflammatory autoimmune diseases.
Moreover, IL-6 has been suggested to be involved in the
pathology of cancer. High levels of circulating IL-6 are ob-
served in almost all types of cancer and predict a poor
outcome [7]. IL-6 levels correlate negatively with Hb levels
in advanced untreated epithelial ovarian cancer patients
[8]. There is direct evidence that recombinant human IL-6
(rhIL-6) treatment as an antitumor immunotherapy in-
duces anemia in cancer patients and that this anemia is re-
versible after the cessation of rhIL-6 treatment [9].
IL-6 is a key factor in inducing hepcidin production.
IL-6 directly regulates hepcidin through induction and
subsequent promoter binding of signal transducer and
activator of transcription 3 (STAT3) [10]. IL-6 has been
reported to elevate hepcidin mRNA expression levels in
freshly isolated mouse hepatocytes and in cells of the
human hepatoma cell line HepG2 [11, 12]. Moreover,
there is a report that immunodeficient mice bearing
hepcidin-producing tumor xenografts developed severe
anemia despite abundant dietary iron, and had lower
serum iron and increased hepatic iron compared with
mice with control tumors [13]. In a clinical report, injec-
tion of rhIL-6 into healthy human volunteers led to an
increase in urinary hepcidin-25 levels and a decrease in
serum iron [14]. Tocilizumab, a humanized anti-IL-6 re-
ceptor antibody, rapidly down-regulated circulating hep-
cidin levels in two cases of multicentric Castleman’s
disease (MCD) [15]. Tocilizumab improved anemia of
inflammation in MCD accompanied by down-regulation
of hepcidin, suggesting that IL-6 plays an essential role
in the induction of hepcidin in MCD, although multiple
factors can affect serum hepcidin levels [16]. These re-
ports imply a relationship between IL-6 and hepcidin
production in some disorders.
In a previous study, we established a model of cancer-
related anemia in mice by the subcutaneous inoculation
of cells of the IL-6–producing human lung cancer cell
line LC-06-JCK [17]. The model showed elevated levels
of IL-6 in serum. Hb levels significantly decreased in the
model compared with non–tumor-bearing (NTB) mice,
and the decreased Hb levels were reversed by treatment
with the rat anti-mouse IL-6 receptor antibody MR16-1.
Although MR16-1 is expected to have a strong effect on
increasing Hb levels, the effects of MR16-1 on cancer-
related anemia in terms of iron metabolism are not fully
understood. Therefore, in the present study, we inves-
tigated whether treatment with MR16-1 affects iron
metabolism, and we evaluated the contribution of




The human cancer cell line LC-06-JCK (lung clear cell
carcinoma) was obtained from the Central Institute for
Experimental Animals (Kanagawa, Japan) and was
maintained in vivo in male CAnN.Cg-Foxn1nu/CrlCrlj
nu/nu mice (nude mice; Charles River Laboratories
Japan, Kanagawa, Japan) as previously reported [18].
Animal models
Five-week-old male nude mice were obtained from
Charles River Laboratories Japan. All animals were
maintained under specific pathogen free conditions and
allowed to acclimatize and recover from shipping-related
stress for at least 1 week in our animal facility before
use. The health of the mice was monitored by daily
observation.
Tumors of LC-06-JCK grown in donor nude mice
were resected, and small pieces were subcutaneously
inoculated into host nude mice, as previously described
[18]. Mice were fed irradiated rodent chow and chlori-
nated water ad libitum. The animals were kept in a con-
trolled light–dark cycle (12–12 h). Animal procedures
were approved by the Institutional Animal Care and Use
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Committee at Chugai Pharmaceutical Co., Ltd. All ani-
mal experiments were performed in accordance with the
Guidelines for the Care and Use of Laboratory Animals
at Chugai Pharmaceutical Co., Ltd.
Administration of rat anti-mouse IL-6 receptor
monoclonal antibody
Rat anti-mouse IL-6 receptor antibody MR16-1 was pro-
duced by the method previously reported [19]. In the
first experiment, the mice were randomly allocated to
control and treatment groups. MR16-1 was administered
intraperitoneally at a dose of 20 mg/kg once a week to
male nude mice bearing LC-06-JCK tumors, starting
15 days after inoculation with LC-06-JCK tumor pieces,
when the tumors were sufficiently established in the
mice. Mice in the control group were administered an
equal dose of rat immunoglobulin G (IgG) purchased
from MP Biomedicals (Solon, Ohio, USA). Rat IgG was
dissolved in distilled water (Otsuka Pharmaceutical,
Tokyo, Japan) and both MR16-1 and rat IgG were di-
luted to appropriate concentrations with saline (Otsuka
Pharmaceutical). Mice were euthanized by exsanguin-
ation under anesthesia with isoflurane before starting
treatment with MR16-1 or rat IgG (0 weeks), or at 2 or
4 weeks after start of treatment.
In the second experiment, the mice were randomly allo-
cated to control and treatment groups. MR16-1 was intra-
peritoneally administered at a dose of 40 mg/kg once a
week to male nude mice bearing LC-06-JCK tumors,
starting 16 days after inoculation with LC-06-JCK tumor
pieces. Mice were euthanized by exsanguination under
anesthesia with isoflurane, and blood was collected before
starting treatment with MR16-1 or rat IgG (0 weeks) or
5 weeks (1 week after final administration of MR16-1 or
rat IgG) after start of treatment. The tumor volume was
estimated by using the equation V = ab2/2, where a and b
are tumor length and width, respectively. Tumor volume
and body weights were measured in the morning.
Specimen collection
Mice were euthanized by exsanguination under anesthesia
with isoflurane, and blood was collected into Minicollect
ethylenediaminetetraacetic acid (EDTA) tubes and Minicol-
lect serum tube (Greiner Bio-One, Kremsmünster, Austria).
Blood samples were analyzed immediately to determine
hematological parameters, and serum was isolated accord-
ing to the manufacturer’s instructions and stored at −80 °C
until use for assays.
Measurement of hematological and iron-related
parameters and cytokines
Hematological parameters were measured by an auto-
mated hematology analyzer KX-21NV (Sysmex Cor-
poration, Hyogo, Japan). The levels of cytokines and
albumin present in serum were determined by using
commercially available ELISA kits for human IL-6,
mouse erythropoietin (EPO) (R&D Systems, Minneapolis,
MN, USA), mouse serum amyloid A (Life Technologies
Japan, Tokyo, Japan), mouse albumin (Shibayagi, Gunma,
Japan), and ferritin (ALPCO Diagnostics, Salem, NH,
USA). Serum iron level was determined by QuantiChrom
Iron Assay Kit (BioAssay Systems, Hayward, CA, USA).
Mouse interleukin-1β (IL-1β), tumor necrosis factor-α
(TNF-α), and IL-6 were measured by Bio-Plex Pro cyto-
kine assays according to the manufacturer’s instructions
(Bio-Rad Laboratories, Hercules, CA, USA). The assays
were performed using the Bio-Plex Pro II wash station
with magnetic plate carrier, and cytokines were deter-
mined by the Bio-Plex 200 System (Bio-Rad Laboratories).
Measurement of mouse serum hepcidin-25
Concentrations of mouse serum hepcidin were mea-
sured by a sensitive liquid chromatography/electrospray
ionization tandem mass spectrometry (LC/ESI–MS/
MS) method using a 4000 QTRAP (AB Sciex, Foster
City, CA, USA) equipped with an ACQUITY Ultra
Performance LC system (Waters, Tokyo, Japan) as pre-
viously reported [20, 21].
Statistical analysis
Statistical analysis was performed by Wilcoxon test
using JMP software (SAS Institute, Cary, NC, USA). A
P value of <0.05 was considered statistically significant.
Data are represented as mean and SD.
Results
LC-06-JCK–bearing mice developed anemia with
decreased values of Hb, hematocrit, and MCV with the
elevation of human IL-6 levels produced from xenografts
To further investigate the anemia observed in the
LC-06-JCK–bearing mice reported in our previous
study, we first confirmed the reproducibility of our
established experimental model in terms of develop-
ment of anemia and production of human IL-6 from
the xenograft.
We detected high levels of human IL-6 in mice in
the IgG-treated LC-06-JCK–bearing control group (TB
group) in a time-dependent manner, and we confirmed
that IL-6 was produced in levels as high as previously
reported [17] (Fig. 1a). We also confirmed that we
were not able to detect human IL-6 in mice in the
NTB group as they did not bear tumors. The values of
Hb, hematocrit (HCT), and mean corpuscular volume
(MCV) were lower in the TB group than the respective
values in the NTB group at 4 weeks (Fig. 1b–d). We
observed no significant differences in human IL-6
levels between LC-06-JCK–bearing mice with or with-
out MR16-1 treatment. MR16-1 treatment significantly
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reversed the decline of Hb, HCT, and MCV values in
this model.
MR16-1 treatment ameliorated cancer-related symptoms
in the LC-06-JCK model
Diseases associated with overexpression of hepcidin are
often microcytic and hypochromic [22]. Because the
anemia in this model was observed to be microcytic, we
used the model to investigate iron-related parameters in
order to clarify the hypothesis that overproduction of
IL-6, a positive regulator of hepcidin, elevates hepcidin
levels and disturbs iron metabolism.
We first investigated cancer-related symptoms in
these mice. Body weight loss was observed in the TB
group as compared to the NTB group at 5 weeks after
start of treatment, and MR16-1-treated LC-06-JCK–
bearing mice (MR16-1 group) showed a significant
increase in body weight as compared to the TB group
(Table 1). We confirmed that, as previously reported,
albumin levels decreased in the TB group and that
levels of albumin increased after 5-week treatment with
MR16-1.
IL-6 is known to be involved in the inflammatory
response; thus, we examined whether the acute-phase re-
action was elevated in this model. We measured the levels
of serum amyloid A (SAA), a hepatic acute-phase reactant
that is known to be increased in response to inflammation
and certain cytokines, particularly IL-6 [23]. The TB group
had a dramatic increase in circulating SAA levels com-
pared to the NTB group at 0 weeks and after treatment
for 5 weeks. On the other hand, the elevation of SAA
levels was significantly inhibited in the MR16-1 group as
compared to the TB group. We also assessed whether in-
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Weeks after start of treatment
Fig. 1 Changes in the parameters during the development of anemia in the LC-06-JCK mouse model. a Human IL-6 levels, b Hb levels, c HCT
levels, and d MCV values were measured in mice treated for 0, 2, and 4 weeks. Open squares, NTB group; open circles, TB group; closed circles,
MR16-1 group. Results are the mean + SD for 8 mice in each group. * P < 0.05, age-matched NTB group versus TB group (Wilcoxon test); # P < 0.05, TB
group versus MR16-1 group (Wilcoxon test)
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volume. There were no differences in tumor volume be-
tween the TB and MR16-1 groups (Table 1).
Treatment with MR16-1 relieved decreased Hb and HCT
despite lack of change in red blood cell counts and
erythropoietin levels in the LC-06-JCK model
We next measured hematological parameters to assess
the status of anemia in this model. Hb and HCT levels
declined in the TB group as compared to the NTB
group, and the decrease in each of these parameters was
significantly inhibited by MR16-1 treatment (Fig. 2a–b).
Red blood cell (RBC) counts were elevated in the TB
group as compared to the NTB group, and treatment
with MR16-1 did not affect RBC counts (Fig. 2c). EPO
levels were elevated in the TB group as compared to the
NTB group; however, we were not able to detect a sig-
nificant difference between EPO levels in the TB and












Fig. 2 Effects of MR16-1 on hematological parameters in the LC-06-JCK mouse model. a Hb levels, b HCT levels, c RBC counts, and d serum EPO
levels were measured in mice treated for 5 weeks. Results are from 18–20 mice in each group. * P < 0.05, age-matched NTB group versus TB
group (Wilcoxon test); # P < 0.05, TB group versus MR16-1 group (Wilcoxon test)
Table 1 Effects of MR16-1 on cancer-related symptoms in the LC-06-JCK mouse model
0 weeks 5 weeks
NTB TB NTB TB MR16-1
Body weight (g) 25.5 ± 1.4 25.8 ± 1.3 28.0 ± 1.1 24.5 ± 2.0* 25.9 ± 2.0**
Albumin (mg/mL) 28.9 ± 3.0 26.5 ± 5.1* 25.5 ± 3.8 16.7 ± 2.6* 22.1 ± 2.8**
SAA (μg/mL) 60.7 ± 95.7 589.2 ± 614.8* 24.8 ± 12.7 5638.0 ± 2867.5* 353.0 ± 302.9**
Tumor volume (mm3) ND 143.9 ± 43.0 ND 1369.9 ± 301.5 1647.6 ± 515.8
Body weight, serum albumin levels, SAA levels, and tumor volumes were measured in mice before treatment (0 weeks) and after being treated for 5 weeks.
Results are the mean ± SD for 19–20 mice in each group. *P < 0.05, age-matched NTB group versus TB group (Wilcoxon test); **P < 0.05, TB group versus MR16-1
group (Wilcoxon test)
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Treatment with MR16-1 inhibited the increase in hepcidin
and ferritin levels in the LC-06-JCK model
We hypothesized that functional iron deficiency—which
is often observed in anemia of inflammation—might be
occurring in LC-06-JCK–bearing mice, and we investigated
iron metabolism-related parameters to assess anemia status.
Since IL-6 is a key inflammatory regulator of hepcidin,
which is the major regulator of iron metabolism, we exam-
ined whether circulating hepcidin levels were elevated in
LC-06-JCK–bearing mice. The TB group showed high
levels of serum hepcidin at 5 weeks after treatment as
compared to NTB mice (Fig. 3a). Moreover, the administra-
tion of MR16-1 statistically decreased the elevation of
circulating hepcidin levels in LC-06-JCK–bearing mice.
As the iron-regulatory hormone hepcidin was increased
in this model, we next measured serum ferritin levels,
which correlate with iron stores in most physiological and
pathological conditions. The TB group showed higher
levels of ferritin as compared to the NTB group;
moreover, MR16-1 treatment reduced ferritin levels in
LC-06-JCK–bearing mice (Fig. 3b). As it is known that
ferritin synthesis is driven by inflammation, we mea-
sured pro-inflammatory cytokines that are reported to
affect ferritin levels to explore the contribution of
these cytokines to ferritin levels. TNF-α and IL-1β
levels were elevated in the TB group as compared to
the NTB group, and treatment with MR16-1 decreased
these levels (Fig. 3c–d). In contrast, although mouse
IL-6 levels were also elevated in the TB group as com-
pared to the NTB group, MR16-1 treatment led to a
further increase in IL-6 levels (Fig. 3e).
Treatment with MR16-1 inhibited the decrease in
MCV and MCH values, leading to improvement of
iron-deficiency anemia in the LC-06-JCK model
To investigate whether reduced iron availability was oc-
curring in this model, we analyzed parameters of circu-
lating erythrocytes and serum iron levels. MCV values
decreased in the TB group as compared to the NTB









































































































Fig. 3 Effects of MR16-1 on iron indices and pro-inflammatory cytokines in the LC-06-JCK mouse model. a Murine hepcidin levels, b murine ferritin levels,
c murine TNF-α levels, d murine IL-1β levels, and e murine IL-6 levels were measured in mice treated for 5 weeks. Results are the mean + SD for 19–20
mice in each group. * P< 0.05, age-matched NTB group versus TB group (Wilcoxon test); # P< 0.05, TB group versus MR16-1 group (Wilcoxon test)
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increased MCV values in this anemia model (Fig. 4a).
Mean corpuscular hemoglobin (MCH) values also de-
creased in the TB group as compared to the NTB group,
and MR16-1 treatment increased MCH values in LC-06-
JCK–bearing mice (Fig. 4b). The TB group showed sta-
tistically low levels of serum iron as compared to the
NTB group (Fig. 4c). We were not able to detect any sig-
nificant difference in serum iron levels between the TB
and MR16-1 groups treated for 5 weeks.
Discussion
We previously established an LC-06-JCK mouse model
of anemia that showed high levels of IL-6 and low levels
of Hb. In this study, we further investigated iron metab-
olism to assess whether the blockade of IL-6 signaling
could prevent anemia in this IL-6–overproducing xeno-
graft model.
MCV and HCT levels were observed to decrease with
the development of cancer-related anemia, implying that
the anemia observed in this model was microcytic
(Fig. 1c–d). The TB group showed anemia as Hb and
HCT levels that were significantly lower than the NTB
group, with elevated RBC counts and EPO levels (Fig. 2).
MR16-1 treatment inhibited the decrease of Hb and
HCT levels and improved anemia in the LC-06-JCK
model. Elevated EPO levels were observed in the TB
group, implying that the response to anemia was not im-
paired in this mouse model; therefore, EPO production
might increase as a compensatory response to the
anemia status. MR16-1 treatment inhibited the decrease
of Hb and HCT levels and improved anemia without
having an impact on RBC counts or EPO levels in the
LC-06-JCK model. Hypoxic and anemic conditions are
known to increase the synthesis of the hormone EPO
which leads to the production of erythrocytes [24];
therefore, we measured EPO levels in this mouse model.
Although EPO production and RBC counts were ele-
vated in the TB group, anemia with decreased Hb levels
was observed; therefore, disturbance of iron metabolism
might be the underlying cause of the anemia observed in
the LC-06-JCK model. We therefore investigated iron
metabolism-related parameters to assess anemia status.
The TB group showed high levels of hepcidin and fer-

























































Fig. 4 Effects of MR16-1 on iron metabolism-related parameters in the LC-06-JCK mouse model. a MCV values, b MCH values, and c serum iron
levels were measured in mice treated for 5 weeks. Results are the mean + SD for 19–20 mice in each group. * P < 0.05, age-matched NTB group
versus TB group (Wilcoxon test); # P < 0.05, TB group versus MR16-1 group (Wilcoxon test)
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serum iron (Figs. 3 and 4); the microcytic and hypochro-
mic anemia observed in the LC-06-JCK–bearing mice
suggested that increased hepcidin production might have
inhibited iron utilization and led to iron-deficiency
anemia. Therefore, the major cause of anemia observed
in LC-06-JCK–bearing mice might be the increase in
hepcidin production through IL-6 signaling leading to
suppression of iron utilization. The increased MCV
values, MCH values, and Hb levels after MR16-1 treat-
ment demonstrate the effective utilization of iron for Hb
synthesis (Figs. 2 and 3). Importantly, treatment of LC-06-
JCK–bearing mice with MR16-1 inhibited the increase in
serum hepcidin levels induced by IL-6 signaling (Fig. 3).
These results imply that MR16-1 ameliorated iron-
deficiency anemia via reduction of hepcidin, which conse-
quently led to the amelioration of iron deficiency.
We hypothesized that excess hepcidin may interfere
with erythropoiesis by inhibiting iron release from hep-
atic storage as ferritin levels were high in this model and
by inhibiting iron uptake from diet and export from
enterocytes to blood as serum iron level was decreased,
consequently possibly causing iron deficiency in the
bone marrow, leading to decreased Hb and MCV levels.
Blockade of IL-6 signaling might inhibit these phenom-
ena in this model. In anemia of chronic disease (ACD),
IL-6 is reported to suppress erythropoiesis by a direct
mechanism and by indirect mechanisms mediated by
other cytokines. IL-6 directly inhibited proliferation of
burst-forming units-erythroid (BFU-E) and colony-forming
units-erythroid (CFU-E) in bone marrow cultures from
healthy donors and from rheumatoid arthritis patients [25].
Elevated levels of IL-6 were found in the supernatants of
bone marrow cultures from patients with ACD, suggesting
that IL-6 local production in bone marrow is possibly asso-
ciated with ACD [26, 27]. Moreover, IL-6 is reported to
impair mitochondrial function in maturating erythroid
cells resulting in impaired Hb production and erythroid
maturation [28]. IL-6 seems to play several roles in the
anemia of cancer by acting at the level of the bone marrow
by inducing ineffective erythropoiesis and at the level of
the reticuloendothelial system by changing iron diversion
by up-regulating hepcidin.
Although hepcidin levels statistically decreased in the
MR16-1 group as compared to the TB group, the sup-
pression was partial (Fig. 3a). Similar phenomena was
reported that hepcidin is up-regulated in multiple mye-
loma patients by both IL-6-dependent and -independent
mechanisms [29]. Hepcidin-independent mechanisms
are also reported to play an important role in murine
models of anemia of cancer [30]. These results suggest
that hepcidin is regulated mainly by IL-6 but that other
factors may also contribute to its regulation. For ex-
ample, hepcidin is known to be up-regulated by some
cytokines in inflammation; on the other hand, EPO is
known as a factor to decrease hepcidin expression levels
[21]. There is some evidence indicating that EPO de-
creases hepcidin mRNA expression levels in several cell
lines and mice [11, 12, 31]. However, in our results,
there was no difference in serum EPO levels between
IgG-treated and MR16-1–treated LC-06-JCK–bearing
mice. So, although EPO production might increase as a
compensatory response to the anemia status, MR16-1
treatment improved anemia without decreasing EPO
levels, and EPO is reported to decrease hepcidin expres-
sion levels [21]. From all of these results taken together,
and because no significant difference between EPO
levels in the TB and MR16-1 groups was observed, EPO
have little contribution to the reduction of hepcidin level
by MR16-1 treatment. Therefore, at least, the contribu-
tion of EPO to hepcidin levels can be excluded (Fig. 2d).
Shortage of serum iron was observed as the increased
demand of iron for erythropoiesis, as shown in the in-
crease of MCV levels was still partial in MR16-1 treated
mice. Therefore, we think that EPO is still required to
enhance erythropoiesis in LC-06-JCK mice, although
MR16-1 treatment improved anemia status.
We observed the decrease of pro-inflammatory cytoki-
nes—TNF-α and IL-1β, for example—their decrease was
also partial (Fig. 3). Some acute-phase proteins may still
interfere with some aspects of iron metabolism despite
statistically restored Hb and hepcidin levels. It is re-
ported that α-1-antitrypsin blocks erythroid-cell iron
uptake and impairs erythropoiesis [32]. TNF-α, known
as an important contributor to the syndrome of cancer
cachexia and other chronic inflammatory conditions,
diseases in which ferritin levels are frequently altered,
and another pro-inflammatory cytokine interleukin-1α
(IL-1α) transcriptionally induces the H chain of ferritin,
suggesting that pathways related to inflammation and
stress can have an impact on ferritin regulation [33]. We
observed high levels of TNF-α and IL-1β in the TB
group, and MR16-1 treatment decreased these levels
(Fig. 3). Ferritin levels also increased in the TB group,
and these cytokines may contribute to this production.
Mouse IL-6 levels increased in the MR16-1 group as
compared to the TB group; on the other hand, the eleva-
tion of SAA levels, downstream of IL-6 signaling, was
significantly inhibited in the MR16-1 group (Table 1).
Because IL-6 is thought to be an important cause of the
anemia of inflammation by inducing hepcidin expression
[14], we used SAA levels as an indicator of IL-6 activity.
These results suggest that IL-6 signaling was sufficiently
blocked by MR16-1 treatment. Since SAA is an acute-
phase reactant that is produced in the liver during
acute-phase response particularly by IL-6 [23], our re-
sults suggest that IL-6 signaling is down-regulated in the
liver of MR16-1-treated TB mice. Similar findings have
been reported in that although tocilizumab treatment
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decreased TNF-α and IL-1β levels, serum IL-6 levels
were increased by tocilizumab therapy regardless of the
improvements in clinical measures in rheumatoid arth-
ritis patients [34]. It is reported that levels of IL-6 in
serum increase when IL-6 receptor is blocked by toci-
lizumab because IL-6 receptor-mediated consumption of
IL-6 is inhibited by the unavailability of tocilizumab-free
IL-6 receptors [35]. Alleviation of cancer-related symp-
toms by MR16-1 treatment seems to contribute to the
reduction of TNF-α and IL-1β levels rather than the
MR16-1 treatment having a direct impact on their levels
by the blockade of IL-6 signaling. Importantly, although
IL-6 levels, a positive regulator of hepcidin, were in-
creased after MR16-1 treatment, hepcidin levels were
significantly decreased with MR16-1 treatment (Fig. 3a);
therefore, it is suggested that the improvement of iron-
deficiency status might be the main mechanism of the
alleviation of anemia by MR16-1 treatment. Further ana-
lysis is needed to reveal the precise mechanisms under-
lying cancer-related anemia.
Serum iron levels decreased in the TB group as com-
pared to the NTB group; however, we were not able to
detect any significant difference in serum iron levels
resulting from MR16-1 treatment (Fig. 4c). As a possible
explanation, neutralizing IL-6 signaling by MR16-1 in-
creases erythropoiesis in bone marrow, which leads to
an increase in the demand for iron to produce iron-
sufficient Hb synthesis. Consequently, the release of iron
into plasma from iron storage is not sufficient to main-
tain homeostatic iron levels. In fact, a similar transient
discrepancy between bone marrow iron availability and
requirements during increased erythropoietic activity is
observed despite the use of oral iron supplements in
chronic dialysis patients and healthy individuals who re-
ceived EPO treatment for anemia [36]. EPO therapy
induced a reduction in serum iron and desaturation of
transferrin, which is associated with iron-deficient erythro-
poiesis [37]. It seems that increased erythropoietic activity
induces transient serum iron deficiency.
We observed inhibition of decreased body weight and
serum albumin levels, and suppressed SAA level in the
LC-06-JCK model mice treated with MR16-1 (Table 1).
We demonstrated that inhibition of IL-6 signaling by
MR16-1 treatment resulted in not only the reduction of
elevated hepcidin levels which led to the improvement
of anemia status but also the systemic amelioration of
disease symptoms. The role of IL-6 in cancer progres-
sion has been reported [38]. In this study, we were not
able to detect any differences in tumor growth between
the TB and MR16-1 groups (Table 1), and there was no
correlation between tumor volume and human IL-6
levels (data not shown), suggesting that amelioration of
cancer-related symptoms was not due to regression of
tumors in the LC-06-JCK model. Importantly, MR16-1
interacts only with the murine IL-6 receptor and is un-
able to cross-react with the human IL-6 receptor [19].
On the other hand, human IL-6 binds to both human
and murine IL-6 receptor [39]; therefore, human IL-6
expressed by tumor cells can act on murine IL-6 recep-
tor expressed in mice.
The involvement of IL-6 has been emphasized in cer-
tain disorders, and tocilizumab has been demonstrated
to be highly efficacious in the treatment of rheumatoid
arthritis, systemic juvenile idiopathic arthritis, and Cas-
tleman’s disease [40]. In terms of clinical implications, it
has been reported that functional IL-6 receptor blocking
is feasible and safe in epithelial ovarian cancer patients
treated with carboplatin/(pegylated liposomal) doxorubi-
cin plus tocilizumab [41]. Tocilizumab had a dramatic
effect on cancer cachexia induced by IL-6–overexpress-
ing lung cancer and prolonged survival without chemo-
therapy [42]. Another group also observed favorable
responses to tocilizumab in terms of inflammation, nu-
tritional status, anemia, and performance status in two
patients with cancer-related cachexia [43]. It is suggested
that serum IL-6 can be utilized as a surrogate marker
for evaluating cachexia and prognosis of patients with
chemotherapy-resistant metastatic lung cancer [44].
These reports imply that IL-6 and hepcidin may be key
proteins involved in cancer-related anemia and suggest a
rationale for targeting IL-6 in cancer-related symptoms.
Regulation of IL-6 signaling might be one of the possible
target pathways to treat IL-6-related disorders.
Conclusions
We demonstrated here that blockade of the IL-6 signaling
pathway by MR16-1 resulted in not only the suppression
of elevated hepcidin levels leading to the improvement of
iron-deficiency anemia status but also to amelioration of
cancer symptoms, suggesting that suppression of hepcidin
production by the blockade of IL-6 signaling may alleviate
both anemia of cancer and cancer-related symptoms. Our
data support the hypothesis that increased hepcidin levels
via IL-6 signaling pathways play an etiologic role in
cancer-related anemia by confining iron to cellular stores
and not allowing exploitation of iron for hematopoiesis.
This hypothesis provides a rationale for therapeutic tar-
geting of IL-6 signaling pathways for managing anemia
in cancer patients.
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